PROPETAMPHOS (SAFROTIN)
Method number: |
PV2050 |
|
Matrix: |
Air |
|
Target Concentration: |
0.2 mg/m3 (arbitrary). There is no
OSHA PEL or ACGIH TLV for propetamphos. |
|
Procedure: |
Samples are collected by drawing known volumes of air through
37-mm glass fiber filters (GFFs). Samples are extracted
with toluene and analyzed by gas chromatography (GC) using an
electron capture detector (ECD). |
|
Recommended air volume and sampling rate: |
60 L at 1.0 L/min |
|
Detection limit of the overall procedure (based on the
recommended air volume and the analytical detection limit): |
0.02 mg/m3 |
|
Status of method: |
Stopgap method. This method has been partially evaluated and is
presented for information and trial use only. |
|
Date: January 1989 |
Chemist: Yogi Shah |
Carcinogen And Pesticide Branch OSHA Analytical
Laboratory Salt Lake City, Utah
1. General Discussion
1.1. Background
1.1.1. History of procedure
This evaluation was undertaken to determine the effectiveness of
a GFF as a sampling media for propetamphos.
1.1.2. Toxic effects (This section is for information only and
should not be taken as the basis of OSHA policy).
The following paragraph is excerpted from the book
OCCUPATIONAL DISEASES, A Guide To Their Recognition. Ref.
5.1.)
The organic phosphorus compounds act as irreversible
inhibitors of cholinesterase, thereby allowing the accumulation of
large amounts of acetylcholine. When a critical level of
cholinesterase depletion is reached, usually about 20% of normal,
symptoms and signs of acetylcholine accumulation poisoning become
manifest. Symptoms may include blurred vision, weakness, nausea,
headache, abdominal cramps, chest discomfort and diarrhea. Signs
may include miosis, muscle twitching, salivation, sweating,
tearing, cyanosis, convulsions and coma. (Ref. 5.1.)
Besides being absorbed following inhalation or ingestion,
organophosphorus pesticides are readily absorbed through the intact
skin (Ref. 5.1.). When a particular pesticide has a low dermal
LD50, a skin notation should be added to the TLV or PEL.
Propetamphos has an acute oral LD50 of 119 mg/kg for
male rats and an acute dermal LD50 of 2300 mg/kg for male
rats. (Ref. 5.2.)
By comparison with other organophosphorus insecticide 0.2
mg/m3, without a skin notation, was used
in this evaluation.
1.1.3. Potential workplace exposure
No estimate of worker exposure to propetamphos could be found.
Propetamphos is used as an insecticide. (Ref.5.2)
1.1.4. Physical properties (Ref. 5-2.-5.4.)
Molecular weight: |
281.31 |
Molecular formula: |
C10H20NO4PS |
CAS #: |
31218-83-4 |
Boiling point: |
87-89°C |
Appearance: |
yellowish oily liquid |
Solubility: |
practically insoluble in water soluble in most
organic solvents |
Synonyms: |
Safrotin, SAN 52139 I, Vel4283 |
Chemical name: |
(E)0-2-isopropoxy-carbonyl-l-methyl vinyl
0-methyl ethylphosphoramido thioatc |
Structure: |
|
1.2. Limit defining parameters
The detection limit of the analytical procedure is 0.013 ng per
injection This is the amount of analyte which will give a peak whose
height is approximately five times the baseline noise. This detection
limit takes into account a split ratio of 32 to 1 used in the
capillary GC.
2. Sampling Procedure
2.1. Apparatus
2.1.1. A personal sampling pump that can be calibrated to within
± 5% of the recommended flow rate with the sampling device in line.
2.1.2. A Glass Fiber Filter, 37-mm diameter, Gelman type A or
equivalent.
2.1.3. A Cassette filter holder for 37-mm filter, Millipore
M000037A0 or equivalent.(see figure 1.)
2.2. Reagents
No sampling reagents are required.
2.3. Sampling technique
2.3.1. Immediately before sampling remove the plastic plugs from
the cassette.
2.3.2. Attach the cassette to the sampling pump with flexible
tubing.
2.3.3. Attach the cassette vertically in the employee's breathing
zone in such a manner that it does not impede work performance.
2.3.4. After sampling for the appropriate time, remove the
cassette and seal with plastic plugs.
2.3.5. Wrap each cassette end-to-end with an OSHA seal (Form 21).
2.3.6. Record the air volume for each sample, and list any
possible interferences.
2.3.7. Submit at least one blank for each set of sample. Handle
the blank in the same manner as the sample, except no air is drawn
through it.
2.3.8. Submit bulk samples for analysis in a separate container.
Do not ship with Air sample.
2.4. Extraction efficiency
Three GFFs were each liquid spiked with 10 µL of a 1.41 mg/mL
solution of propetamphos in toluene. They were then extracted with 3.0
mL of toluene and analyzed as in Section 3. The average recovery was
95.2%.
Table 2.4. Extraction Study
|
Vial # |
Amount spiked |
Amount recovered |
% Recovery |
|
EX 1 |
14.10 µg |
13.76 µg |
97.6 |
EX 2 |
14.10 µg |
12.83 µg |
91.0 |
EX 3 |
14.10 µg |
13.66 µg |
96.9 |
EX 4 |
0.00 µg |
0.00 µg |
Blank |
|
2.5. Retention efficiency
Six GFFs were each liquid spiked with 10 µL of a 1.41 mg/mL
solution of propetamphos in toluene. After overnight storage in a
drawer at room tempreture, 60 liters of humid air were drawn through
each GFF. Three of these GFFs, along with a blank GFF, werc then
extracted and analyzed as in Section 3. The average recovery was
90.3%. The remaining three spiked GFFs were used in the storage study.
Table 2.5. Retention Efficiency Study
|
Sample # |
Amount spiked |
Amount recovered |
% Recovery |
|
RET 1 |
14.10 µg |
13.30 µg |
94.4 |
RET 2 |
14.10 µg |
12.60 µg |
89.4 |
RET 3 |
14.10 µg |
12.29 µg |
87.1 |
RET 4 |
0.00 µg |
0.00 µg |
Blank |
|
2.6. Sample storage
The remaining three spiked GFFs from Section 2.5. (and a blank GFF)
were stored for 8 days in a drawer at room temperature. They were then
extracted and analyzed as in Section 3. The average recovery was
90.4%.
Table 2.6. Storage Study
|
Sample # |
Amount spiked |
Amount recovered |
% Recovery |
|
ST 1 |
14.10 µg |
13.10 µg |
93.6 |
ST 2 |
14.10 µg |
12.65 µg |
89.7 |
ST 3 |
14.10 µg |
12.39 µg |
87.9 |
ST 4 |
0.00 µg |
0.00 µg |
Blank |
|
2.7. Recommended air volume and sampling rate
2.7.1. The recommended air volume is 60 L.
2.7.2. The recommended flow rate is 1.0 L/min.
2.8. Interferences (sampling)
It is not known if any compounds will interfere with the collection
of propetamphos. Suspected interferences should be reported to the
laboratory with submitted samples.
2.9. Safety precautions (sampling)
2.9.1. Attach the sampling equipment in such a manner that it
will not interfere with work performance or employee safety.
2.9.2. Follow all safety practices that apply to the work area
being sampled.
3. Analytical Procedure
3.1. Apparatus
3.1.1. A GC with an ECD. A Hewlett-Packard 5890A GC (capillary)
equipped with both an ECD and a Hewlett-Packard 7673A automatic
sampler was used in this evaluation.
3.1.2. A GC column capable of resolving propetamphos from any
interferences. A 60 m x 0.32 mm i.d. SE-30 GC capillary column, 0.25
µm thick film, was used in this evaluation and is available from
Supelco, Inc., Bellefonte, PA.
3.1.3. An electronic integrator or other suitable means of
measuring detector response. A Hewlett-Packard 3392A Integrator and
a Hewlett-Packard 3357 data system were used in this evaluation.
3.1.4. Vials, 4-mL and 2-mL glass with PTFE-lined septa.
3.1.5. Volumetric flasks, pipets, and syringes.
3.2. Reagents
3.2.1. Hydrogen, air, and nitrogen, GC grade.
3.2.2. Toluene, Pesticide grade.
3.2.3. Propetamphos. A 38.6% (w/w) solution in 1,3,5
trimethyl-benzene from the EPA was used in this evaluation.
3.3. Standard preparation
Prepare stock standards by adding toluene to preweighed amounts of
propetamphos. Prepare working range standards by diluting stock
solutions with toluene. Store stock and dilute standards in a freezer.
3.4. Sample preparation
3.4.1. Transfer the 37-mm glass fiber filter to a 4-mL vial.
3.4.2. Add 3.0 ml. of toluene to each vial.
3.4.3. Seal the vials with Polytetrafluroethlene (PTFE) lined
septa. Allow them to extract for one hour periodically shaking by
hand .
3.4.4. If necessary, transfer aliquots of the samples to the
vials used in GC analysis. In this evaluation the samples were
transferred to 2-mL glass vials, sealed with PTFE lined septa, and
loaded on the automatic sampler.
3.5. Analysis
3.5.1. Analytical conditions
GC conditions |
|
GC column: |
60 m x 0.32 mm i.d. SE-30, 0.25 µm |
|
thick film |
Column temperature: |
220°C (isothermal) |
Carrier gas: |
Hydrogen |
Flow rate: |
1.97 mL/min |
Split ratio: |
32 to 1 |
Retention time:
|
3.47 min
|
Injector conditions |
|
Temperature: |
230°C |
Volume:
|
1 µL
|
ECD conditions |
|
Air flow rate: |
100 mL./min |
Auxiliary gas: |
Nitrogen |
Flow rate: |
20 mL/min |
Temperature: |
300°C |
3.5.2. Chromatogram (See Figure 2.)
3.6. Interferences (analytical)
3.6.1. Any compound having a retention time similar to that of
the analyte is a potential interference. Generally, chromatographic
conditions can be altered to separate interferences from the
analyte.
3.6.2. Retention time on a single column is not proof of chemical
identity. Analysis by an alternate GC column, flame photometric
detector (FPD) and confirmation by mass spectrometry are additional
means of identification.
3.7. Calculations
3.7.1. Construct a calibration curve by plotting detector
response versus standard concentration.
3.7.2. Determine the concentration of propetamphos in samples and
blank from the calibration curve. If propetamphos is found in the
blank make a blank correction.
3.7.3. Determine the air concentration by the following formula.
mg/m3 = |
(µg/mL in sample) × (extraction
volume, mL)
(air volume, L) × (extraction efficiency,
decimal) |
3.8. Safety precautions (analytical)
3.8.1. Avoid exposure to all standards.
3.8.2. Avoid exposure to all solvents.
3.8.3. Wear safety glasses at all times.
4. Recommendations for Further Study
4.1. An OSHA Versatile Sampler (OVS-2) packed with XAD-2 adsorbent
should be evaluated as a sampling device for propetamphos.
4.2. A fully validated method should be developed.
Figure 1. Sampling Device
Figure 2. Chrbmatogram of propetamphos
5. References
5.1. "OCCUPATIONAL DISEASES, A Guide to their Recognition"; U.S.
Department of Health, Education, and Welfare; Public Health Service,
Public Health Service Publication No. 1097, U.S. Government Printing
Office; Washington, D.C., 1964; p 245.
5.2. "Farm Chemicals Handbook"; Meister Publishing Co.; Willoughby,
OH, 1985; p C195.
5.3. Windholz, M., Ed.; "Merck Index", 10th ed.; Merck and Co.;
Rahway, NJ, 1983; p 1126.
5.4. Registry of Toxic Effects of Chemical Substances, 1978
Edition. (Lewis, R.J. and Tatken, R.L., Eds.) U.S. Department of
Health, Education and Welfare, Public Health Services, Center for
Disease Control, National Institute for Occupational Safety and
Health, U.S. Government Printing Office, Washington, D.C.(1978).
|